

MODELOS ANIMALES Y CELULARES PARA LA DETECCIÓN Y CARACTERIZACIÓN DE CÉLULAS MADRE LEUCÉMICAS

Alvarez-Larran, A; Perez-Encinas, M; Ferrer-Marin, F; Hernandez-Boluda, JC; Ramirez, MJ; Martinez-Lopez, J; Magro, E; Cruz, Y; Mata, MI; Aragues, MP; Fox, ML; Cuevas, B; Montesdeoca, S; Hernandez-Rivas, JA; Garcia-Gutierrez, V; Gomez-Casares, MT; Steegmann, JL; Duran, MA; Gomez, M; Kerguelen, A; Barez, A; Garcia, MC; Boque, C; Raya, JM; Martinez, C; Albors, M; Garcia, F; Burgaleta, C; Besses, C. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. HAEMATOLOGICA. 2017; 102(1):103-109.Article. IF -7,702

Alvaro-Blanco, J; Urso, K; Chiodo, Y; Martin-Cortazar, C; Kourani, O; Gomez-del Arco, P; Rodriguez-Martinez, M; Calonge, E; Alcami, J; Redondo, JM; Iglesias, T; Campanero, MR. MAZ induces MYB expression during the exit from quiescence via the E2F site in the MYB promoter. NUCLEIC ACIDS RESEARCH. 2017; 45(17):9960-9975.Article. IF -10,162

Cadenas, FL; Xicoy, B; Bargay, J; Sanz, G; Amigo, ML; Arrizabalaga, B; Bernal, T; De Paz, R; Sanchez, J; Nomdedeu, B; Rivas, JAH; Fenaux, P; Slama, B; Giagounidis, A; Lumbreras, E; Thepot, S; Platzbecker, U; Coll, R; Redondo, A; Roldan, MCD; Diez-Campelo, M. PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY OF SINTRA-REV CLINICAL TRIAL, LENALIDOMIDE VS PLACEBO PHASE 3 STUDY IN LOW/INT-1 MDS PATIENTS WITH DEL(5Q) AND TRANSFUSION INDEPENDENCY. HAEMATOLOGICA. 2017; 102():484-485.Meeting Abstract. IF -7,702

Cadenas, FL; Xicoy, B; Sanchez, J; Fenaux, P; Rivas, JAH; Amigo, ML; Coll, R; Lumbreras, E; Slama, B; Bernal, T; De Paz, R; Platzbecker, U; Giagounidis, A; Nomdedeu, B; Thepot, S; Sanz, G; Arrizabalaga, B; Bargay, J; Fernandez-Roldan, MCD; Diez-Campelo, M. SINTRA-REV CLINICAL TRIAL: PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY AT WEEK 12 OF TREATMENT IN MDS DEL(5Q) AND TRANSFUSION INDEPENDENCE. LEUKEMIA RESEARCH. 2017; 55():S52-S52.Meeting Abstract. IF -2,501

Cortez, S; De Paz, R; Gasior, M; Martinez, A; Mozo, Y; Rosich, B; Valentin, J; Sastre, A; Perez, A. MEMORY T CELLS DONOR LYMPHOCYTE INFUSIONS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION AS A SAFE PROCEDURE TO IMPROVE T-CELL RECONSTITUTION. HAEMATOLOGICA. 2017; 102:630-630.Meeting Abstract. IF -7,702

De La Iglesia, S; Morado, M; Arrizabalaga, B; Gonzalez, A; Beneitez, D; Rubio, ML; Recasens, V; Salido, E; Urquia, A; Rodriguez, I; Piernas, S; Martin, X; Chavez, C; Lemes, A; Acosta, C; Villegas, AM; Sehh, GDE. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND APLASTIC ANAEMIA - DATA FROM THE SPANISH PNH REGISTRY. HAEMATOLOGICA. 2017; 102():705-705.Meeting Abstract. IF -7,702

Font, P; Subira, D; Matarraz, S; Benavente, C; Cedena, T; Morado, M; Perez-Corral, A; Bellon, JM; Diez-Martin, JL. MULTICENTER COMPARISON OF CD34+MYELOID CELL COUNT BY FLOW CYTOMETRY IN LOW-RISK MYELODYSPLASTIC SYNDROME. IS IT FEASIBLE?. LEUKEMIA RESEARCH. 2017; 55:S98-S99.Meeting Abstract. IF -2,501

Hernandez-Boluda, JC; Correa, JG; Garcia-Delgado, R; Martinez-Lopez, J; Alvarez-Larran, A; Fox, ML; Garcia-Gutierrez, V; Perez-Encinas, M; Ferrer-Marin, F; Mata-Vazquez, MI; Raya, JM; Estrada, N; Garcia, S; Kerguelen, A; Duran, MA; Albors, M; Cervantes, F. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. EUROPEAN JOURNAL OF HAEMATOLOGY. 2017; 98(4):407-414.Article. IF -2,653

Hernandez-Boluda, J-C; Pereira, A; Correa, J-G; Alvarez-Larran, A; Ferrer-Marin, F; Raya, J-M; Martinez-Lopez, J; Perez-Encinas, M; Estrada, N; Velez, P; Fox, M-L; Garcia-Gutierrez, V; Payer, A; Kerguelen, A; Cuevas, B; Duran, M-A; Ramirez, M-J; Gomez-Casares, M-T; Mata-Vazquez, M-I; Mora, E; Martinez-Valverde, C; Gomez, M; Cervantes, F. Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis.. Leukemia. 2017:-.Article. IF -11,702

Hernandez-Boluda, Juan-Carlos; Correa, Juan-Gonzalo; Alvarez-Larran, Alberto; Ferrer-Marin, Francisca; Raya, Jose-Maria; Martinez-Lopez, Joaquin; Velez, Patricia; Perez-Encinas, Manuel; Estrada, Natalia; Garcia-Gutierrez, Valentin; Fox, Maria-Laura; Luno, Elisa; Kerguelen, Ana; Cuevas, Beatriz; Duran, Maria-Antonia; Ramirez, Maria-Jose; Gomez-Casares, Maite; Mata-Vazquez, Maria-Isabel; Regadera, Anabel; Pereira, Arturo; Cervantes, Francisco. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia.. British journal of haematology. 2017:-.Letter. IF -5,67

Hiddemann, W; Barbui, AM; Albendea, MAC; Cannell, PK; Collins, GP; Durig, J; Forstpointner, R; Herold, M; Hertzberg, M; Klanova, M; Radford, JA; Tobinai, K; Burciu, A; Fingerle-Rowson, GR; Nielsen, T; Wolbers, M; Marcus, RE. IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN. HAEMATOLOGICA. 2017; 102:314-314.Meeting Abstract. IF -7,702

Hughes, T; Boquimpani, C; Takahashi, N; Benyamini, N; Clementino, NC; Shuvaev, V; Ailawadhi, S; Lipton, J; Turkina, A; de Paz, R; Moiraghi, B; Nicolini, F; Dengler, J; Sacha, T; Kim, DW; Fellague-Chebra, R; Acharya, S; Kronic, N; Jin, Y; Mahon, FX. DURABLE TREATMENT-FREE REMISSION AFTER STOPPING SECOND-LINE NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: ENESTOP 96-WK UPDATE. HAEMATOLOGICA. 2017; 102:75-75.Meeting Abstract. IF -7,702

Kabat, MG; Badell, I; Torrent, M; Sisinni, L; Querol, S; Gimeno, R; Soria, L; Bueno, D; Sanroman, S; Plaza, D; De Paz, R; Marcos, A; Torres, J; Granados, EL; Sastre, A;

Valentin, J; Perez-Martinez, A. Clinical Outcome and Immune Cell Recovery after C45RA-Depleted Haplodentical Transplantation in Paediatric Patients with High Risk Acute Leukemia. PEDIATRIC BLOOD & CANCER. 2017; 64:S98-S98.Meeting Abstract. IF -2,513

Lahuerta, JJ; Paiva, B; Vidriales, MB; Cordon, L; Cedena, MT; Puig, N; Martinez-Lopez, J; Rosinol, L; Gutierrez, NC; Martin-Ramos, ML; Oriol, A; Teruel, AI; Echeveste, MA; de Paz, R; de Arriba, F; Hernandez, MT; Palomera, L; Martinez, R; Martin, A; Alegre, A; De la Rubia, J; Orfao, A; Mateos, MV; Blade, J; San-Miguel, JF. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. JOURNAL OF CLINICAL ONCOLOGY. 2017; 35(25):2900+.Article. IF -24,008

Maerevoet, M; Westin, J; Thieblemont, C; Zijlstra, J; Hill, BT; Vicente, FD; Choquet, S; Caimi, P; Kaplan, J; Canales, MA; Kuruvilla, J; Follows, G; Van den Neste, E; Meade, J; Wrigley, B; Devlin, M; Saint-Martin, JR; Nippgen, C; Gardner, H; Shacham, S; Kauffman, MG; Casasnovas, RO. SINGLE AGENT ORAL SELINEXOR EXHIBITS DURABLE RESPONSES IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF BOTH GCB AND NON-GCB SUBTYPES: THE PHASE 2B SADAL STUDY. HAEMATOLOGICA. 2017; 102():173-174.Meeting Abstract. IF -7,702

Martin, MIG; Albendea, MAC; Urdiola, MF; Ortigueira, MDMM; Yuste, VJ. FLAG-IDA IN THE TREATMENT OF ACUTE LEUKEMIA: SINGLE-CENTER EXPERIENCE. HAEMATOLOGICA. 2017; 102:682-682.Meeting Abstract. IF -7,702

Martinez-Velandia, A; Gasior, M; de Paz, R; Cortez, S; Bueno, D; Sastre, A; Canales, M; Perez-Martinez, A. REDUCED INCIDENCE OF PRIMARY GRAFT FAILURE IN PATIENTS UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE. HAEMATOLOGICA. 2017; 102:636-637.Meeting Abstract. IF -7,702

Montero, LFC; Garcia-Gutierrez, JV; Giraldo, P; Perez-Encinas, M; de Paz, R; Martinez-Lopez, J; Bautista, G; Osorio, S; Requena, MJ; Palomera, L; Penarrubia, MJ; Calle, C; Hernandez-Rivas, JA; Garcia-Ormena, N; Mba, C; Steegmann, JL. HEMATOLOGIC TOXICITY GRADE III-IV IS ASSOCIATED WITH LOWER SURVIVAL IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS. HAEMATOLOGICA. 2017; 102:432-433.Meeting Abstract. IF -7,702

Morado, M; Freire Sandes, A; Colado, E; Subira, D; Isusi, P; Noya, MS; Vidriales, MB; Sempere, A; Diaz, JA; Minguela, A; Alvarez, B; Serrano, C; Caballero, T; Rey, M; Corral, AP; Jimenez, MCF; Magro, E; Lemes, A; Benavente, C; Banas, H; Merino, J; Castejon, C; Gutierrez, O; Rabasa, P; Goncalves, MV; Perez-Andres, M; Orfao, A. Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications. CYTOMETRY PART B-CLINICAL CYTOMETRY. 2017; 92(5):361-370.Article. IF -2,474

Nomdedeu, M; Pereira, A; Ramos, F; Valcarcel, D; Costa, D; Arnan, M; Calvo, X; Pomares, H; Luno, E; Diaz-Campelo, M; Collado, R; de Paz, R; Falantes, JF; Pedro, C; Marco, J; Oirtzabal, I; Sanchez-Garcia, J; Tormo, M; Cedena, MT; Nomdedeu, B; Sanz,

G. Excess mortality in the myelodysplastic syndromes. AMERICAN JOURNAL OF HEMATOLOGY. 2017; 92(2):149-154.Article. IF -5,275

Oller, J; Mendez-Barbero, N; Ruiz, EJ; Villahoz, S; Renard, M; Canelas, LI; Briones, AM; Alberca, R; Lozano-Vidal, N; Hurle, MA; Milewicz, D; Evangelista, A; Salaices, M; Nistal, JF; Jimenez-Borreguero, LJ; De Backer, J; Campanero, MR; Redondo, JM. Nitric oxide mediates aortic disease in mice deficient in the metalloprotease Adamts1 and in a mouse model of Marfan syndrome. NATURE MEDICINE. 2017; 23(2):200-212.Article. IF -29,886

Pose-Utrilla, J; Garcia-Guerra, L; Del Puerto, A; Martin, A; Jurado-Arjona, J; De Leon-Reyes, NS; Gamir-Morralla, A; Serrano, AS; Garcia-Gallo, M; Kremer, L; Fielitz, J; Ireson, C; Perez-Alvarez, MJ; Ferrer, I; Hernandez, F; Avila, J; Lasa, M; Campanero, MR; Iglesias, T. Excitotoxic inactivation of constitutive oxidative stress detoxification pathway in neurons can be rescued by PKD1. NATURE COMMUNICATIONS. 2017; 8:-2275.Article. IF -12,124

Ramos, F; Pedro, C; Tormo, M; de Paz, R; Font, P; Luno, E; Caballero, M; Solano, F; Almagro, M; Xicoy, B; Jimenez, M. Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study. EUROPEAN JOURNAL OF CANCER CARE. 2017; 26(6):-e12426.Article. IF -2,104

Ramos, F; Robledo, C; Pereira, A; Pedro, C; Benito, R; de Paz, R; del Rey, M; Insunza, A; Tormo, M; Diez-Campelo, M; Xicoy, B; Salido, E; Sanchez-Del-Real, J; Arenillas, L; Florensa, L; Luno, E; del Canizo, C; Sanz, GF; Hernandez-Rivas, JM. Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group. AMERICAN JOURNAL OF HEMATOLOGY. 2017; 92(9):E534-E541.Article. IF -5,275

Salar, A; Domingo-Domenech, E; Panizo, C; Nicolas, C; Bargay, J; Muntanola, A; Canales, M; Bello, JL; Sancho, JM; Tomas, JF; Rodriguez, MJ; Penalver, J; Grande, C; Sanchez-Blanco, JJ; Palomera, L; Arranz, R; Conde, E; Garcia, M; Garcia, JF; Caballero, D; Montalban, C. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. BLOOD. 2017; 130(15):1772-1774.Letter. IF -13,164

Senent, L; Lorenzo, I; Vicente, A; Alonso, E; Sanzo, C; Ramos, F; Arenillas, L; Orero, M; Navarro, B; Marco, V; Campelo, MD; Jerez, A; Montoro, J; Arrizabalaga, B; Bonanad, S; Lluch, R; Paz, RD; Font, P; Gomis, F; Sanz, G. PROGNOSTIC IMPLICATION OF THE PERCENTAGE OF ERYTHROID CELLS IN BONE MARROW AT DIAGNOSIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME. LEUKEMIA RESEARCH. 2017; 55:S151-S152.Meeting Abstract. IF -2,501

Stegmann, JL; Garcia-Gutierrez, V; Colom, B; Sanchez-Guijo, F; Ayala, R; Boque, C; Casado, F; Xicoy, B; Montero, I; Soto, C; de Paz, R; Kreutzman, A; Martinez-Lopez, J; Munoz, C. EFFICACY OF SWITCHING TO DASATINIB IN CHRONIC MYELOID PATIENTS WITH LATE WARNING RESPONSES TO IMATINIB. STUDY OF THE ASSOCIATION OF RESPONSE TO DASATINIB TO IMMUNOLOGIC STATUS. HAEMATOLOGICA. 2017; 102:239-240.Meeting Abstract. IF -7,702

N° Documentos	Tipo de documento	FI	I° Cuartil	I° Decil
11	Artículos	113,365	9	7
2	Cartas	18,834	2	1
14	Meeting Abstract	87,036	11	10
	FI Originales	113,365		
	FI Total	219,235		